Terms ending in 2033
Every in-force patent on Pfizer Inc.'s record whose computed term ends in 2033, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 8,680,111 | Macrocyclic Derivatives for the Treatment of Diseases In force · High confidence | Pfizer Inc. | In force | High confidence | |
| US 9,133,215 | Macrocyclic Derivatives for the Treatment of Diseases In force · High confidence | Pfizer Inc. | In force | High confidence | |
| US 8,986,710 | Neisseria Meningitidis Compositions and Methods Thereof In force · High confidence | Pfizer Inc. | In force | High confidence | |
| US 9,561,269 | Neisseria Meningitidis Compositions and Methods Thereof In force · High confidence | Pfizer Inc. | In force | High confidence | |
| US 9,724,402 | Neisseria Meningitidis Composition and Methods Thereof In force · High confidence | Pfizer Inc. | In force | High confidence | |
| US 10,196,429 | Neisseria Meningitidis Composition and Methods Thereof In force · Medium confidence | Pfizer Inc. | In force | Medium confidence | |
| US 10,550,159 | Neisseria Meningitidis Composition and Methods Thereof In force · High confidence | Pfizer Inc. | In force | High confidence | |
| US 10,829,521 | Neisseria Meningitidis Composition and Methods Thereof In force · High confidence | Pfizer Inc. | In force | High confidence | |
| US 8,889,730 | Indole and Indazole Compounds That Activate Ampk In force · High confidence | Pfizer Inc. | In force | High confidence | |
| US 9,394,285 | Indole and Indazole Compounds that Activate AMPK In force · Medium confidence | Pfizer Inc. | In force | Medium confidence | |
| 47 more term ends in 2033 · Pro | |||||
10 of 57 patents shown. Soonest term end first, then patent number.
Pro members see all 57.
52 of these are in force and held by Pfizer Inc..
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.